8 results
Autoantibodies in Rheumatology
 • Lupus (SLE): ANA (anti-nuclear antibody), dsDNA (double-stranded DNA), Anti-Smith, Anti-Ro (SSA) and
Rheumatology • ... Lupus (SLE): ANA ... IllANCA Vasculitis ... #Rheumatology # ... diagnosis #associations
CNS Manifestations of Systemic Lupus Erythematosus (SLE)

Clinical Manifestations: Demyelinating Syndrome, Headache, Movement disorders, Seizure disorders, Aseptic
of Systemic Lupus ... Cerebrovascular Disease ... #SLE #CNS #neurology ... #rheumatology # ... #management #treatment
SLE (Systemic Lupus Erythematosus)

Suspect:
Clinical evidence of (fatigue, rash, photosensitivity, inflammatory arthritis, weight loss, and fever) and
SLE (Systemic Lupus ... Diagnosis: • ANCA-associated ... and CNS • Headache ... #Systemic #Lupus ... #Diagnosis #Rheumatology
Antinuclear antibodies and Systemic lupus
Anti-dsDNA	60-80%	Association with disease activity (when with Farr assay) and lupus nephritis. Can
and Systemic lupus ... with disease activity ... with auto-immune diseases ... #diagnosis #rheumatology ... #table #ANA
Drug Induced Lupus vs SLE
Drug Induced Lupus (DIL):
 • Epidemiology: -10% of all lupus cases, drug-dependent,
of autoantibodies ... Lupus Erythematosus ... : Chronic disease ... #table #rheumatology ... #diagnosis #management
Behçet's Syndrome
Systemic disease associated with inflammation of multiple organs, small-vessel vasculitis and large-vessel vasculopathy
Epidemiology:
 • Young
Systemic disease ... Asia • HLA-B51 association ... ) Differential Diagnosis ... #diagnosis #management ... #rheumatology #
TAFRO

TAFRO syndrome was first described in 2010, standing for:
- Thrombocytopenia
- Anasarca
- Fever
- Reticulin fibrosis
- Organomegaly

TAFRO syndrome
multicentric Castleman disease ... lupus erythematosus ... infection, rickettsial disease ... , Lyme disease, ... #management #rheumatology
Anti-NXP-2 Dermatomyositis

What?
DM with generalized subcutaneous edema
Pts have more myalgias, more severe weakness, and an increased prevalence
without these autoantibodies ... • Antibodies targeting ... levels • NXP-2 antibody ... had more severe disease ... #management #rheumatology